These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 35403540)

  • 1. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose.
    Hu S; Liu L; Pollock RF; Pöhlmann J; Wu D; Zhang Y
    J Med Econ; 2022; 25(1):561-570. PubMed ID: 35403540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
    Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
    J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China.
    Zhang F; Shen A; Ahmed W; Pollock RF
    Adv Ther; 2024 Nov; 41(11):4191-4204. PubMed ID: 39292421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
    Pollock RF; Biggar P
    Expert Rev Hematol; 2020 Feb; 13(2):187-195. PubMed ID: 31928094
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery.
    Auerbach M; Achebe MM; Thomsen LL; Derman RJ
    Obes Surg; 2022 Mar; 32(3):810-818. PubMed ID: 35000068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
    Pollock RF; Muduma G
    J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
    [No Abstract]   [Full Text] [Related]  

  • 7. A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.
    Pollock RF; Kalra PA; Kalra PR; Ahmed FZ
    Adv Ther; 2022 Oct; 39(10):4678-4691. PubMed ID: 35947351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose.
    Kennedy NA; Achebe MM; Biggar P; Pöhlmann J; Pollock RF
    Int J Clin Pharm; 2023 Jun; 45(3):604-612. PubMed ID: 37010731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure.
    Ambrosy AP; von Haehling S; Kalra PR; Court E; Bhandari S; McDonagh T; Cleland JGF
    Am J Cardiol; 2021 Aug; 152():138-145. PubMed ID: 34162484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the efficacy and safety of intravenous infusion of ferric derisomaltose in the treatment of iron deficiency anemia: a single-center retrospective analysis].
    Ding SX; Zhao YH; Wang T; Guan J; Xing LM; Liu H; Wang GJ; Wang XM; Wu YH; Qu W; Song J; Wang HQ; Li LJ; Shao ZH; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):178-183. PubMed ID: 38604795
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study.
    Kawabata H; Tamura T; Tamai S; Fujibayashi A; Sugimura M;
    Int J Hematol; 2022 Nov; 116(5):647-658. PubMed ID: 35790696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the Management of Iron Deficiency in China: A Rapid Health Technology Assessment.
    Yun L; YuMei Z; Bn V; Tang Q; Feng C
    Cureus; 2023 Nov; 15(11):e48717. PubMed ID: 38094535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland.
    Pollock RF; Muduma G
    Clinicoecon Outcomes Res; 2021; 13():9-18. PubMed ID: 33442276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland.
    Loughnane F; Muduma G; Pollock RF
    Adv Ther; 2020 Mar; 37(3):1218-1232. PubMed ID: 32030608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Hypophosphatemia After Intravenous Administration of Iron: A Matching-Adjusted Indirect Comparison of Data from Japanese Randomized Controlled Trials.
    Fukumoto S; Murata T; Osuga Y; Pollock RF
    Adv Ther; 2023 Nov; 40(11):4877-4888. PubMed ID: 37702931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF; Muduma G
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial.
    Auerbach M; Henry D; Derman RJ; Achebe MM; Thomsen LL; Glaspy J
    Am J Hematol; 2019 Sep; 94(9):1007-1014. PubMed ID: 31243803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
    Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
    PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
    Bhandari S; Kalra PA; Berkowitz M; Belo D; Thomsen LL; Wolf M
    Nephrol Dial Transplant; 2021 Jan; 36(1):111-120. PubMed ID: 32049331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.
    Derman R; Roman E; Modiano MR; Achebe MM; Thomsen LL; Auerbach M
    Am J Hematol; 2017 Mar; 92(3):286-291. PubMed ID: 28052413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.